Why CSL’s returns outperform CBA, says Daniel Moore, portfolio manager at Investors Mutual

When the share price of sleep apnea treatment device maker ResMed fell nearly 40 percent from peak to trough last year on concerns that the weight-loss wonder drug Ozempic would shrink the market for people seeking treatment for sleep disorders, the buyer was Daniel Moore of Investors Mutual.

He saw ResMed’s weakened share price as an opportunity to buy shares whose fortunes had tilted toward more bearish experts.

Loading…